Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

208.37 +6.71 (+3.33%)
Streaming Delayed Price Updated: 12:38 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗
Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks. 
Via Benzinga
News headline image
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings ↗
 
Via Benzinga
News headline image
Channel Therapeutics Stock Soars On Announcement Of Subsidiary’s Merger With Ligand Pharma Units: Retail’s Elated ↗
Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel. 
Via Stocktwits
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Demystifying Ligand Pharmaceuticals: Insights From 10 Analyst Reviews ↗
 
Via Benzinga
News headline image
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals ↗
 
Via Benzinga
News headline image
Dow Falls Over 1%; US Initial Jobless Claims Decline ↗
 
Via Benzinga
Topics Stocks
News headline image
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity ↗
Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs. 
Via Benzinga
News headline image
Analyst Sees Big Upside In Ligand's Capital-Efficient Biotech Strategy ↗
Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth. 
Via Benzinga
News headline image
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Assessing Ligand Pharmaceuticals: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings For Ligand Pharmaceuticals ↗
 
Via Benzinga
News headline image
Looking Into Ligand Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
News headline image
Ligand to Present at Stifel 2024 Healthcare Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
From Palvella Therapeutics
Via GlobeNewswire
News headline image
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
News headline image
LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 ↗
LGND stock results show that Ligand Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.